Loading…

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients

Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activato...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-10, Vol.25 (20), p.11028
Main Authors: Gavriilaki, Eleni, Demosthenous, Christos, Evangelidis, Paschalis, Bousiou, Zoi, Batsis, Ioannis, Vardi, Anna, Mallouri, Despina, Koravou, Eudoxia-Evaggelia, Spyridis, Nikolaos, Panteliadou, Alkistis, Karavalakis, Georgios, Masmanidou, Marianna, Touloumenidou, Tasoula, Papalexandri, Apostolia, Poziopoulos, Christos, Yannaki, Evangelia, Sakellari, Ioanna, Politou, Marianna, Papassotiriou, Ioannis
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3
container_end_page
container_issue 20
container_start_page 11028
container_title International journal of molecular sciences
container_volume 25
creator Gavriilaki, Eleni
Demosthenous, Christos
Evangelidis, Paschalis
Bousiou, Zoi
Batsis, Ioannis
Vardi, Anna
Mallouri, Despina
Koravou, Eudoxia-Evaggelia
Spyridis, Nikolaos
Panteliadou, Alkistis
Karavalakis, Georgios
Masmanidou, Marianna
Touloumenidou, Tasoula
Papalexandri, Apostolia
Poziopoulos, Christos
Yannaki, Evangelia
Sakellari, Ioanna
Politou, Marianna
Papassotiriou, Ioannis
description Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group ( < 0.001, in all comparisons). SuPAR levels at baseline were associated with the m-EASIX scores calculated at the same time point ( = 0.020), while suPAR and GDF-15 concentrations were correlated with EASIX scores at day 14 post-infusion ( < 0.001 in both comparisons). Moreover, sC5b-9 levels were correlated with the s-EASIX scores at infusion ( = 0.008) and the EASIX scores at day 14 ( = 0.005). In our study, sC5b9, suPAR, and GDF-15 levels were found to reflect endothelial injury in CAR-T cell recipients.
doi_str_mv 10.3390/ijms252011028
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11507105</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120646055</sourcerecordid><originalsourceid>FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3</originalsourceid><addsrcrecordid>eNpdkktrGzEUhYfS0qRpl90WQTcOdFo9RjOjVRmc2A0YGhxnPcjSHVuuLLnSjIN_bv9J5eZB0tW5cD_OORduln0k-CtjAn8zm22knGJCMK1fZaekoDTHuKxeP5tPsncxbjCmjHLxNjthouBlTfBp9ufG22FpAd0G_8s4GSFfHHaArq2MW-P8ChxqVG_2svcBzUHB7jiM4nDdzM-_oGnwd_0aXZiugwCuN7I33qGJVAnLCUej6cUkaUKl0-gxbcyXuUgu__QczWAPNqImALoxK2c6o6Tr7QE1MXqVPEGjO5NyLp32_RqskRZduc0QDkm0URCRcWjczPMFGoO1x6ZmZ1Kh-D5700kb4cODnmW3k8vF-Ec--zm9GjezXDFM-7ySZUU7XkMhqKiowCWTndClqBVoyatCc81ETZRkrJZCLoWsOyF1VxdcF0qzs-z7ve9uWG5Bq5QdpG13wWxlOLRemvblxpl1u_L7lhCOK4J5chg9OAT_e4DYt1sTVbpGOvBDbBmhBJdY0CKhn_9DN34ILt13pHBZlJgfDfN7SgUfY4DuqQ3B7fF72hffk_hPz094oh_fhf0F9_LBPA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120646055</pqid></control><display><type>article</type><title>Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Gavriilaki, Eleni ; Demosthenous, Christos ; Evangelidis, Paschalis ; Bousiou, Zoi ; Batsis, Ioannis ; Vardi, Anna ; Mallouri, Despina ; Koravou, Eudoxia-Evaggelia ; Spyridis, Nikolaos ; Panteliadou, Alkistis ; Karavalakis, Georgios ; Masmanidou, Marianna ; Touloumenidou, Tasoula ; Papalexandri, Apostolia ; Poziopoulos, Christos ; Yannaki, Evangelia ; Sakellari, Ioanna ; Politou, Marianna ; Papassotiriou, Ioannis</creator><creatorcontrib>Gavriilaki, Eleni ; Demosthenous, Christos ; Evangelidis, Paschalis ; Bousiou, Zoi ; Batsis, Ioannis ; Vardi, Anna ; Mallouri, Despina ; Koravou, Eudoxia-Evaggelia ; Spyridis, Nikolaos ; Panteliadou, Alkistis ; Karavalakis, Georgios ; Masmanidou, Marianna ; Touloumenidou, Tasoula ; Papalexandri, Apostolia ; Poziopoulos, Christos ; Yannaki, Evangelia ; Sakellari, Ioanna ; Politou, Marianna ; Papassotiriou, Ioannis</creatorcontrib><description>Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group ( &lt; 0.001, in all comparisons). SuPAR levels at baseline were associated with the m-EASIX scores calculated at the same time point ( = 0.020), while suPAR and GDF-15 concentrations were correlated with EASIX scores at day 14 post-infusion ( &lt; 0.001 in both comparisons). Moreover, sC5b-9 levels were correlated with the s-EASIX scores at infusion ( = 0.008) and the EASIX scores at day 14 ( = 0.005). In our study, sC5b9, suPAR, and GDF-15 levels were found to reflect endothelial injury in CAR-T cell recipients.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms252011028</identifier><identifier>PMID: 39456810</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adult ; Aged ; Biomarkers - blood ; Disease ; FDA approval ; Female ; Growth Differentiation Factor 15 - blood ; Growth Differentiation Factor 15 - metabolism ; Hematology ; Humans ; Immunotherapy ; Immunotherapy, Adoptive - adverse effects ; Immunotherapy, Adoptive - methods ; Lymphocytes ; Lymphoma ; Male ; Middle Aged ; Mortality ; Multivariate analysis ; Pathophysiology ; Receptors, Urokinase Plasminogen Activator - blood ; Receptors, Urokinase Plasminogen Activator - metabolism ; Regression analysis</subject><ispartof>International journal of molecular sciences, 2024-10, Vol.25 (20), p.11028</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3</cites><orcidid>0000-0003-0011-6997 ; 0000-0002-2008-7954 ; 0000-0003-1783-5111 ; 0000-0002-8883-8208 ; 0000-0002-2126-3251</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3120646055/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3120646055?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39456810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gavriilaki, Eleni</creatorcontrib><creatorcontrib>Demosthenous, Christos</creatorcontrib><creatorcontrib>Evangelidis, Paschalis</creatorcontrib><creatorcontrib>Bousiou, Zoi</creatorcontrib><creatorcontrib>Batsis, Ioannis</creatorcontrib><creatorcontrib>Vardi, Anna</creatorcontrib><creatorcontrib>Mallouri, Despina</creatorcontrib><creatorcontrib>Koravou, Eudoxia-Evaggelia</creatorcontrib><creatorcontrib>Spyridis, Nikolaos</creatorcontrib><creatorcontrib>Panteliadou, Alkistis</creatorcontrib><creatorcontrib>Karavalakis, Georgios</creatorcontrib><creatorcontrib>Masmanidou, Marianna</creatorcontrib><creatorcontrib>Touloumenidou, Tasoula</creatorcontrib><creatorcontrib>Papalexandri, Apostolia</creatorcontrib><creatorcontrib>Poziopoulos, Christos</creatorcontrib><creatorcontrib>Yannaki, Evangelia</creatorcontrib><creatorcontrib>Sakellari, Ioanna</creatorcontrib><creatorcontrib>Politou, Marianna</creatorcontrib><creatorcontrib>Papassotiriou, Ioannis</creatorcontrib><title>Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group ( &lt; 0.001, in all comparisons). SuPAR levels at baseline were associated with the m-EASIX scores calculated at the same time point ( = 0.020), while suPAR and GDF-15 concentrations were correlated with EASIX scores at day 14 post-infusion ( &lt; 0.001 in both comparisons). Moreover, sC5b-9 levels were correlated with the s-EASIX scores at infusion ( = 0.008) and the EASIX scores at day 14 ( = 0.005). In our study, sC5b9, suPAR, and GDF-15 levels were found to reflect endothelial injury in CAR-T cell recipients.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Disease</subject><subject>FDA approval</subject><subject>Female</subject><subject>Growth Differentiation Factor 15 - blood</subject><subject>Growth Differentiation Factor 15 - metabolism</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy, Adoptive - adverse effects</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Pathophysiology</subject><subject>Receptors, Urokinase Plasminogen Activator - blood</subject><subject>Receptors, Urokinase Plasminogen Activator - metabolism</subject><subject>Regression analysis</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNpdkktrGzEUhYfS0qRpl90WQTcOdFo9RjOjVRmc2A0YGhxnPcjSHVuuLLnSjIN_bv9J5eZB0tW5cD_OORduln0k-CtjAn8zm22knGJCMK1fZaekoDTHuKxeP5tPsncxbjCmjHLxNjthouBlTfBp9ufG22FpAd0G_8s4GSFfHHaArq2MW-P8ChxqVG_2svcBzUHB7jiM4nDdzM-_oGnwd_0aXZiugwCuN7I33qGJVAnLCUej6cUkaUKl0-gxbcyXuUgu__QczWAPNqImALoxK2c6o6Tr7QE1MXqVPEGjO5NyLp32_RqskRZduc0QDkm0URCRcWjczPMFGoO1x6ZmZ1Kh-D5700kb4cODnmW3k8vF-Ec--zm9GjezXDFM-7ySZUU7XkMhqKiowCWTndClqBVoyatCc81ETZRkrJZCLoWsOyF1VxdcF0qzs-z7ve9uWG5Bq5QdpG13wWxlOLRemvblxpl1u_L7lhCOK4J5chg9OAT_e4DYt1sTVbpGOvBDbBmhBJdY0CKhn_9DN34ILt13pHBZlJgfDfN7SgUfY4DuqQ3B7fF72hffk_hPz094oh_fhf0F9_LBPA</recordid><startdate>20241014</startdate><enddate>20241014</enddate><creator>Gavriilaki, Eleni</creator><creator>Demosthenous, Christos</creator><creator>Evangelidis, Paschalis</creator><creator>Bousiou, Zoi</creator><creator>Batsis, Ioannis</creator><creator>Vardi, Anna</creator><creator>Mallouri, Despina</creator><creator>Koravou, Eudoxia-Evaggelia</creator><creator>Spyridis, Nikolaos</creator><creator>Panteliadou, Alkistis</creator><creator>Karavalakis, Georgios</creator><creator>Masmanidou, Marianna</creator><creator>Touloumenidou, Tasoula</creator><creator>Papalexandri, Apostolia</creator><creator>Poziopoulos, Christos</creator><creator>Yannaki, Evangelia</creator><creator>Sakellari, Ioanna</creator><creator>Politou, Marianna</creator><creator>Papassotiriou, Ioannis</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0011-6997</orcidid><orcidid>https://orcid.org/0000-0002-2008-7954</orcidid><orcidid>https://orcid.org/0000-0003-1783-5111</orcidid><orcidid>https://orcid.org/0000-0002-8883-8208</orcidid><orcidid>https://orcid.org/0000-0002-2126-3251</orcidid></search><sort><creationdate>20241014</creationdate><title>Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients</title><author>Gavriilaki, Eleni ; Demosthenous, Christos ; Evangelidis, Paschalis ; Bousiou, Zoi ; Batsis, Ioannis ; Vardi, Anna ; Mallouri, Despina ; Koravou, Eudoxia-Evaggelia ; Spyridis, Nikolaos ; Panteliadou, Alkistis ; Karavalakis, Georgios ; Masmanidou, Marianna ; Touloumenidou, Tasoula ; Papalexandri, Apostolia ; Poziopoulos, Christos ; Yannaki, Evangelia ; Sakellari, Ioanna ; Politou, Marianna ; Papassotiriou, Ioannis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Disease</topic><topic>FDA approval</topic><topic>Female</topic><topic>Growth Differentiation Factor 15 - blood</topic><topic>Growth Differentiation Factor 15 - metabolism</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy, Adoptive - adverse effects</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Pathophysiology</topic><topic>Receptors, Urokinase Plasminogen Activator - blood</topic><topic>Receptors, Urokinase Plasminogen Activator - metabolism</topic><topic>Regression analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gavriilaki, Eleni</creatorcontrib><creatorcontrib>Demosthenous, Christos</creatorcontrib><creatorcontrib>Evangelidis, Paschalis</creatorcontrib><creatorcontrib>Bousiou, Zoi</creatorcontrib><creatorcontrib>Batsis, Ioannis</creatorcontrib><creatorcontrib>Vardi, Anna</creatorcontrib><creatorcontrib>Mallouri, Despina</creatorcontrib><creatorcontrib>Koravou, Eudoxia-Evaggelia</creatorcontrib><creatorcontrib>Spyridis, Nikolaos</creatorcontrib><creatorcontrib>Panteliadou, Alkistis</creatorcontrib><creatorcontrib>Karavalakis, Georgios</creatorcontrib><creatorcontrib>Masmanidou, Marianna</creatorcontrib><creatorcontrib>Touloumenidou, Tasoula</creatorcontrib><creatorcontrib>Papalexandri, Apostolia</creatorcontrib><creatorcontrib>Poziopoulos, Christos</creatorcontrib><creatorcontrib>Yannaki, Evangelia</creatorcontrib><creatorcontrib>Sakellari, Ioanna</creatorcontrib><creatorcontrib>Politou, Marianna</creatorcontrib><creatorcontrib>Papassotiriou, Ioannis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gavriilaki, Eleni</au><au>Demosthenous, Christos</au><au>Evangelidis, Paschalis</au><au>Bousiou, Zoi</au><au>Batsis, Ioannis</au><au>Vardi, Anna</au><au>Mallouri, Despina</au><au>Koravou, Eudoxia-Evaggelia</au><au>Spyridis, Nikolaos</au><au>Panteliadou, Alkistis</au><au>Karavalakis, Georgios</au><au>Masmanidou, Marianna</au><au>Touloumenidou, Tasoula</au><au>Papalexandri, Apostolia</au><au>Poziopoulos, Christos</au><au>Yannaki, Evangelia</au><au>Sakellari, Ioanna</au><au>Politou, Marianna</au><au>Papassotiriou, Ioannis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-10-14</date><risdate>2024</risdate><volume>25</volume><issue>20</issue><spage>11028</spage><pages>11028-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group ( &lt; 0.001, in all comparisons). SuPAR levels at baseline were associated with the m-EASIX scores calculated at the same time point ( = 0.020), while suPAR and GDF-15 concentrations were correlated with EASIX scores at day 14 post-infusion ( &lt; 0.001 in both comparisons). Moreover, sC5b-9 levels were correlated with the s-EASIX scores at infusion ( = 0.008) and the EASIX scores at day 14 ( = 0.005). In our study, sC5b9, suPAR, and GDF-15 levels were found to reflect endothelial injury in CAR-T cell recipients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39456810</pmid><doi>10.3390/ijms252011028</doi><orcidid>https://orcid.org/0000-0003-0011-6997</orcidid><orcidid>https://orcid.org/0000-0002-2008-7954</orcidid><orcidid>https://orcid.org/0000-0003-1783-5111</orcidid><orcidid>https://orcid.org/0000-0002-8883-8208</orcidid><orcidid>https://orcid.org/0000-0002-2126-3251</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2024-10, Vol.25 (20), p.11028
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11507105
source Publicly Available Content Database; PubMed Central; Coronavirus Research Database
subjects Adult
Aged
Biomarkers - blood
Disease
FDA approval
Female
Growth Differentiation Factor 15 - blood
Growth Differentiation Factor 15 - metabolism
Hematology
Humans
Immunotherapy
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Lymphocytes
Lymphoma
Male
Middle Aged
Mortality
Multivariate analysis
Pathophysiology
Receptors, Urokinase Plasminogen Activator - blood
Receptors, Urokinase Plasminogen Activator - metabolism
Regression analysis
title Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A40%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20Urokinase-Type%20Plasminogen%20Activator%20Receptor%20(suPAR),%20Growth%20Differentiation%20Factor-15%20(GDF-15),%20and%20Soluble%20C5b-9%20(sC5b-9)%20Levels%20Are%20Significantly%20Associated%20with%20Endothelial%20Injury%20Indices%20in%20CAR-T%20Cell%20Recipients&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Gavriilaki,%20Eleni&rft.date=2024-10-14&rft.volume=25&rft.issue=20&rft.spage=11028&rft.pages=11028-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms252011028&rft_dat=%3Cproquest_pubme%3E3120646055%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c302t-7a672f58e4929729063af9d698ceda574d5d3981ca338a9ab9a8f9adf845d4cd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3120646055&rft_id=info:pmid/39456810&rfr_iscdi=true